ReviewEuropean journal of medical research2025
Potential benefits of vitamin A and its derivatives in glaucoma.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Vitamin A (VA), which plays a vital role in maintaining normal eye functions, has shown potential benefits in glaucoma based on accumulating evidence. The purpose of this review is to comprehensively summarize the possible role of VA and VA derivatives in the prevention and treatment of glaucoma, explore their mechanisms of action, suggest future research directions, and provide references for relevant researchers. Regarding the correlation between VA intake and glaucoma, researchers in different regions have conducted a series of studies, but most of them are cross-sectional studies. The results of different studies vary greatly and there are conflicting results, but the results of several systematic reviews and meta-analysis suggest that dietary VA intake can help reduce the risk of glaucoma. If increasing total dietary VA intake is successful as an effective prevention strategy, this would be a promising approach for primary prevention of glaucoma. Further, we summarized a large number of mechanism studies which have demonstrated the mechanisms of how VA might play a role in the prevention and treatment of glaucoma by inhibiting the oxidative stress process of trabecular meshwork and optic nerve tissue, reversing the effect of TGF-β2 on human trabecular meshwork cells and increasing intracranial pressure. Additionally, studies have also shown that VA and its derivatives could also play a role in preventing postoperative scarring and damage of the ocular surface due to the use of antiglaucoma drugs through a variety of mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.